| US 7,524,969 B2 | ||
| Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | ||
| Thomas Arrhenius, Del Mar, Calif. (US); Mi Chen, San Diego, Calif. (US); Jie Fei Chang, Carlsbad, Calif. (US); Yujin Huang, San Diego, Calif. (US); Alex Michael Nadzan, Encinitas, Calif. (US); Richard Julius Penuliar, San Diego, Calif. (US); David Mark Wallace, San Diego, Calif. (US); Lin Zhang, San Diego, Calif. (US); Gary D. Lopaschuk, Edmonton (Canada); and Jason R. Dyck, Sherwood Park (Canada) | ||
| Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (Japan) | ||
| Appl. No. 10/466,923 PCT Filed Jan. 22, 2002, PCT No. PCT/US02/01789 § 371(c)(1), (2), (4) Date Jul. 21, 2003, PCT Pub. No. WO02/058698, PCT Pub. Date Aug. 01, 2002. |
||
| Claims priority of provisional application 60/264552, filed on Jan. 26, 2001. | ||
| Prior Publication US 2004/0082576 A1, Apr. 29, 2004 | ||
| Int. Cl. C07D 277/00 (2006.01) | ||
| U.S. Cl. 548—190 | 5 Claims |
1. A compound of the formula:
 R3 is hydrogen; C1-C8 alkyl unsubstituted or substituted with C1-C6 alkoxy, pyridyl, furanyl, methylimidazolyl, thiazolyl, phenyl or substituted phenyl, wherein the substituent is cyano, C1-C6 alkyl, halo, dihalo, methylsulfonyl, carboxy, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, teterazolyl or carboxyvinyl;
R4 is hydrogen; C1-C8 alkyl unsubstituted or substituted with one or two C1-C6 alkoxy, carboxy, C1-C6 alkoxycarbonyl or phenyl; cyclohexyl; phenyl unsubstituted or substituted with one or two halo; or pyridyl;
R5 is hydrogen;
R7 is halophenyl;
or a pharmaceutically acceptable salt thereof.
|